Skip to main content

Table 1 Baseline Demographics and Disease Characteristics

From: Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer

 

Total Study Cohort(n = 71)

Subset of Subjects with Pretreatment Tissue Biopsies(n = 47)

Remaining Subjects(n = 24)

P-value

Age (years)

   

0.9466

 Mean (SD)

62.54 (10.0)

62.43 (9.2)

62.75 (11.6)

 

 Median

62

62

61.5

 

Age, n(%)

   

0.8108

  < 70

52 (73)

34 (72)

18 (75)

 

  > = 70

19 (27)

13 (28)

6 (25)

 

Sex, n(%)

   

0.5282

 Female

26 (37)

16 (34)

10 (42)

 

 Male

45 (63)

31 (66)

14 (58)

 

ECOG Status, n(%)

   

0.1672

 0

22 (31)

17 (36)

5 (21)

 

 1

44 (62)

28 (60)

16 (67)

 

 2

3 (4)

2 (4)

1 (4)

 

 3

2 (3)

2 (8)

 

Stage, n(%)

   

0.3136

 IIIA

4 (6)

2 (4)

2 (8)

 

 IIIB

8 (11)

7 (15)

1 (4)

 

 IV

59 (83)

38 (81)

21 (88)

 

Histology, n(%)

   

0.4137

 Adenocarcinoma

68 (96)

45 (96)

23 (96)

 

 Adenocarcinoma|Large cell carcinomaa

1 (1)

1 (4)

 

 Adenocarcinoma|Squamous cell carcinomaa

2 (3)

2 (4)

 

1 L Therapy Received, n(%)

   

0.8582

 Chemotherapy Onlyb

31 (44)

21 (45)

10 (42)

 

 Chemo+Radiationc

25 (35)

17 (36)

8 (33)

 

 Chemo+Targetedd

9 (13)

6 (13)

3 (13)

 

 Chemo+Radiation+Targetedd

6 (8)

3 (6)

3 (13)

 

Smoking Status, n(%)

   

0.8495

 Never Smoker

11 (15)

6 (13)

5 (21)

 

 Quit more than 5 years ago

9 (13)

6 (13)

3 (13)

 

 Quit less than 5 years ago

9 (13)

6 (13)

3 (13)

 

 Current Smoker

42 (59)

29 (62)

13 (54)

 
  1. ECOG, Eastern Cooperative Oncology Group; SD, standard deviation. aAll subjects received an initial diagnosis of adenocarcinoma; however, additional histology was reported after re-biopsy; bCisplatin/carboplatin plus pemetrexed; cRadiation included for brain or bone metastatic sites; dTargeted therapy was bevacizumab in 13 subjects, erlotinib plus chemotherapy and radiation in 1 subject, and 1 subject received Nivolumab after chemotherapy and bevacizumab